Kallikrein 11 anticorps (AA 68-82)

N° du produit ABIN636296

Détail du produit anti-Kallikrein 11 anticorps

Antigène: Kallikrein 11 (KLK11)

Épitope: AA 68-82

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Kallikrein 11 est non-conjugé

Application: Western Blotting (WB)

Réactivité croisée: Souris, Rat (Rattus)

Réactivité croisée (Details): This antibodys immunogen shares 86 % sequence identity with the Mouse, and rat homologs.

Purification: Affinity chromatography purified

Immunogène: KLK11 antibody was raised in rabbit using AA 68-82 [YIVHLGQHNLQKEEG] of the 35 kDa human hippostasin/KLK11 protein as the immunogen.

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Détails sur Kallikrein 11

Antigène: Kallikrein 11 (KLK11)

Autre désignation: KLK11 (KLK11 Produits)

Synonymes: anticorps KLK11, anticorps 2310015I08Rik, anticorps Prss20, anticorps TLSP, anticorps PRSS20, anticorps kallikrein related peptidase 11, anticorps kallikrein related-peptidase 11, anticorps kallikrein-related peptidase 11, anticorps KLK11, anticorps Klk11

Sujet: Hippostasin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. Hippostasin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of hK11 were found in 70% of women with ovarian cancer and in 60% of men with prostate cancer.

Pathways: Système du Complément